Diabetic ketoacidosis during therapy for pediatric acute lymphoblastic leukemia
- 11 February 2008
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 50 (6), 1207-1212
- https://doi.org/10.1002/pbc.21505
Abstract
Background Hyperglycemia is common during therapy for acute lymphoblastic leukemia (ALL), but diabetic ketoacidosis (DKA) occurs rarely. Morbidity due to DKA in children with ALL has not been systematically studied. Procedures We reviewed risk factors and clinical consequences of DKA in patients undergoing therapy for ALL at SJCRH between 1991 and 2006. Results DKA occurred in 6 of 797 evaluable patients. Only older age at diagnosis of ALL was a risk factor for DKA. Four of six patients with DKA as compared to 232 of the other 791 patients were older than 10 years (P = 0.03). Race, sex, body mass index, leukemia immunophenotype, ALL risk category, white blood cell count at diagnosis, and treatment protocol were not associated with DKA. All patients were managed with intravenous fluids, dietary modification, and short-term use of insulin. Patients were hospitalized for 4–12 days, with a median ICU stay of 1 day. In two patients, correction of hyperglycemia was too rapid, and two others experienced hypoglycemia due to insulin therapy. There were no permanent complications of DKA or its treatment. No patient required long-term insulin use. No patient had recurrent DKA; only one of the six patients had a subsequent hyperglycemia episode. All six patients are alive in remission 6–13 years after diagnosis. Conclusions Patients with hyperglycemia during treatment for ALL should be screened for clinical evidence of DKA, which may require more intensive supportive care than those without ketoacidosis. The occurrence of DKA should not lead to alteration of ALL treatment. Pediatr Blood Cancer 2008;50:1207–1212.Keywords
This publication has 30 references indexed in Scilit:
- Clinical value of glycated hemoglobin and fructosamine in the long-term glycemic control of children with acute lymphoblastic leukemiaPediatrics International, 2007
- SERUM CYTOKINE DIFFERENCES IN SEVERELY BURNED CHILDREN WITH AND WITHOUT SEPSISShock, 2007
- Hyperglycemic Hyperosmolar Nonketotic Syndrome in a Child With Acute Lymphoblastic Leukemia Undergoing Induction ChemotherapyJournal of Pediatric Hematology/Oncology, 2005
- Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate–cytarabine regimenCancer, 2004
- Dexamethasone‐associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycinCancer, 2003
- Hyperglucagonemia in L-Asparaginase Induced Diabetes MellitusJournal of Pediatric Hematology/Oncology, 1986
- Relative Hyperglucagonemia in L-Asparaginase-and Prednisone-induced Glucose Intolerance in Management of Acute Lymphocytic LeukemiaClinical Pediatrics, 1983
- Risk factors for hyperglycemia in children with leukemia receiving l-asparaginase and prednisoneThe Journal of Pediatrics, 1981
- L-Asparaginase-induced diabetes mellitus in rabbitsDiabetes, 1980
- Hyperglycemia associated with the therapeutic use of l-asparaginase: Possible role of insulin receptorsThe Journal of Pediatrics, 1978